These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 2698471)

  • 21. Cytotoxic activity of an anti-transferrin receptor immunotoxin on normal and leukemic human hematopoietic progenitors.
    Cazzola M; Bergamaschi G; Dezza L; D'Uva R; Ponchio L; Rosti V; Ascari E
    Cancer Res; 1991 Jan; 51(2):536-41. PubMed ID: 1985771
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective cytotoxic activity of immunotoxins composed of a monoclonal anti-Thy 1.1 antibody and the ribosome-inactivating proteins bryodin and momordin.
    Stirpe F; Wawrzynczak EJ; Brown AN; Knyba RE; Watson GJ; Barbieri L; Thorpe PE
    Br J Cancer; 1988 Nov; 58(5):558-61. PubMed ID: 3265330
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro anti-tumour activity of anti-CD80 and anti-CD86 immunotoxins containing type 1 ribosome-inactivating proteins.
    Bolognesi A; Polito L; Tazzari PL; Lemoli RM; Lubelli C; Fogli M; Boon L; de Boer M; Stirpe F
    Br J Haematol; 2000 Aug; 110(2):351-61. PubMed ID: 10971392
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A new 'solid phase' procedure to synthesize immunotoxins (antibody-ribosome inactivating protein conjugates).
    Dosio F; Brusa P; Delprino L; Ceruti M; Grosa G; Cattel L; Bolognesi A; Barbieri L
    Farmaco; 1993 Jan; 48(1):105-15. PubMed ID: 8457275
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting the EGF receptor in breast cancer treatment.
    LeMaistre CF; Meneghetti C; Howes L; Osborne CK
    Breast Cancer Res Treat; 1994; 32(1):97-103. PubMed ID: 7819590
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunotoxins: new therapeutic reagents for autoimmunity, cancer, and AIDS.
    Vitetta ES
    J Clin Immunol; 1990 Nov; 10(6 Suppl):15S-18S. PubMed ID: 2081785
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of immunotoxins bearing a single saporin molecule with multiple toxin conjugates.
    Flavell DJ; Flavell SU
    Methods Mol Biol; 2001; 166():87-100. PubMed ID: 11217378
    [No Abstract]   [Full Text] [Related]  

  • 28. Rationale for the clinical use of immunotoxins: monoclonal antibodies conjugated to ribosome-inactivating proteins.
    Preijers FW
    Leuk Lymphoma; 1993 Mar; 9(4-5):293-304. PubMed ID: 8348066
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Cancer therapy by using bispecific antibody].
    Azuma A; Niitani H; Okumura K
    Gan To Kagaku Ryoho; 1991 Aug; 18(10):1535-42. PubMed ID: 1872618
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunotoxins.
    Kreitman RJ
    Expert Opin Pharmacother; 2000 Sep; 1(6):1117-29. PubMed ID: 11249483
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Production of anti-cancer immunotoxins in algae: ribosome inactivating proteins as fusion partners.
    Tran M; Henry RE; Siefker D; Van C; Newkirk G; Kim J; Bui J; Mayfield SP
    Biotechnol Bioeng; 2013 Nov; 110(11):2826-35. PubMed ID: 23719862
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Amino acid sequence analysis, gene construction, cloning, and expression of gelonin, a toxin derived from Gelonium multiflorum.
    Rosenblum MG; Kohr WA; Beattie KL; Beattie WG; Marks W; Toman PD; Cheung L
    J Interferon Cytokine Res; 1995 Jun; 15(6):547-55. PubMed ID: 7553224
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plant Toxin-Based Immunotoxins for Cancer Therapy: A Short Overview.
    Polito L; Djemil A; Bortolotti M
    Biomedicines; 2016 Jun; 4(2):. PubMed ID: 28536379
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotoxins containing recombinant anti-CTLA-4 single-chain fragment variable antibodies and saporin: in vitro results and in vivo effects in an acute rejection model.
    Tazzari PL; Polito L; Bolognesi A; Pistillo MP; Capanni P; Palmisano GL; Lemoli RM; Curti A; Biancone L; Camussi G; Conte R; Ferrara GB; Stirpe F
    J Immunol; 2001 Oct; 167(8):4222-9. PubMed ID: 11591743
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotoxins in the treatment of hematologic malignancies.
    Kreitman RJ; Pastan I
    Curr Drug Targets; 2006 Oct; 7(10):1301-11. PubMed ID: 17073592
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunotoxins: status and prospects.
    Spooner RA; Lord JM
    Trends Biotechnol; 1990 Jul; 8(7):189-93. PubMed ID: 1366624
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selective killing of CD4+ and CD8+ cells with immunotoxins containing saporin.
    Barbieri L; Bolognesi A; Dinota A; Lappi DA; Soria M; Tazzari PL; Stirpe F
    Scand J Immunol; 1989 Sep; 30(3):369-72. PubMed ID: 2571186
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of growth of breast cancer cells in vitro by the ribosome-inactivating protein saporin 6.
    Gasperi-Campani A; Zoli W; Volpi A; Roncuzzi L; Amadori D
    Anticancer Res; 1991; 11(2):1007-11. PubMed ID: 2064307
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of immunotoxins containing single-chain ribosome-inactivating proteins and an anti-CD22 monoclonal antibody (OM124): in vitro and in vivo studies.
    Bolognesi A; Tazzari PL; Olivieri F; Polito L; Lemoli R; Terenzi A; Pasqualucci L; Falini B; Stirpe F
    Br J Haematol; 1998 Apr; 101(1):179-88. PubMed ID: 9576199
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeted toxins as anticancer agents.
    Siegall CB
    Cancer; 1994 Aug; 74(3 Suppl):1006-12. PubMed ID: 7913661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.